Thuja et al. invest in Hemics

Thuja, Point One and BOM are existing investors in the company, while DFZ is a new backer. DFZ is the investment arm of Dutch health insurance firm De Friesland.

Hemics will use the fresh capital to further develop, clinically test and commercialise its HandScan product.

The company plans to launch the product in selected European hospitals in the coming months, with the first five systems to be provided to the University Medical Centre Utrecht and four non-academic hospitals in the Netherlands.

Previous funding
In September 2011, Hemics (then known as Akeso Medical) secured funding from BOM, Thuja and Point One to spin out from Philips Research.

Thuja invested in the spinout via its Thuja Capital Healthcare Seed Fund, according to unquote" data.

Company
Founded in 2011 and headquartered in Eindhoven, Hemics is a medical device company specialising in the treatment of rheumatoid arthritis.

The company is developing imaging devices that are designed to aid rheumatologists in the monitoring and treatment of the disease.

Its HandScan product is an optical imaging device designed to monitor joint inflammation in the hands and wrists of rheumatoid arthritis patients.

People
Petra van den Elsen is the founder and CEO of Hemics. DFZ investment director Ben Dijk has joined Hemics's board of directors, which already includes Harrold van Barlingen, the founder and managing director of Thuja, who acts as chairman, and Point One senior partner Theo Claasen.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Netherlands